NCT00790699View on ClinicalTrials.gov

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

NATerminatedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Type 1 DiabetesType 2 Diabetes
Interventions
DEVICE

I-PORT

The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.

OTHER

standard injections

The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.

Trial Locations (1)

78731

Texas Diabetes & Endocrinology, PA, Austin

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

Texas Diabetes & Endocrinology, P.A.

OTHER